CBD Europe💯💚


Aurora Cannabis Completes Hempco Food and Fibre Acquisition

Hempco provides Aurora with access to low-cost, high-volume raw hemp material

Aurora identified the potential of hemp-derived CBD early on, completing its first investment in Hempco in 2017, and has subsequently expanded its hemp-based infrastructure through targeted acquisitions and strategic partnerships.

 Aurora Hemp: an integrated operating unit executing the Company’s Global Hemp Strategy.

for the extraction of primarily cannabidiol (“CBD”) and other cannabinoids

With expertise across genetics, extraction, product development, brands and distribution, Aurora Hemp is an end-to-end offering across the entire hemp value chain:


Hempco, a trusted and respected pioneer, innovator and provider of quality, hemp-based foods, hemp fiber, and hemp nutraceuticals. Brands include PLANET HEMP™ and PRAISE, hemp-based foods and nutritional supplements for people and animals. Hempco is nearing completion of a new, state-of-the-art Nisku facility, a 56,000 square foot, 2.9 million kg per year hemp processing facility.

Agropro, Europe’s largest producer of organic hemp and hemp-based food products has extensive experience in sowing seeds, growing, machine harvesting, drying and cleaning biomass in preparation for food processing or extraction into CBD.

Borela, a processor and distributor across the European Union of organic hulled hemp seeds, hemp seed protein, hemp flour, and hemp seed oil.

ICC Labs, a Latin American based producer and distributor of cannabinoid products for recreational and medicinal use with operations in Uruguay and Colombia. ICC has access to high CBD hemp genetics available for export to international jurisdictions.

Anandia Labs, the industry leader in science, genetics, and independent cannabis product testing to provide rigorous product testing and quality assurance, ensuring safe and efficacious consumer products.

Radient Technologies, a provider of industrial-scale manufacturing solutions with a technology platform designed for high extraction and high-volume throughput of cannabinoids available in the plant biomass.

UFC Clinical Research and Product Development, through this partnership Aurora and UFC will research and examine the use of hemp-derived CBD as an effective treatment for pain, inflammation, wound-healing, and recovery on MMA athletes. Research data will then be used to drive the development of a portfolio of science-backed, high-quality, hemp-derived CBD topical treatments, under the new high-performance sports brand ROAR Sports.

“Aurora is defining the future of cannabis and hemp, globally,” said Terry Booth, CEO of Aurora. “Through the addition of Hempco, we have assembled a world-class portfolio of high-quality hemp assets that together form the basis of a strong new operating division that will develop CBD-from-hemp around the world. Aurora Hemp brings together the cultivars, strategic partners, brands, and distribution networks to service medical, consumer, and wellness markets and further advances Aurora’s entry into the US hemp food and hemp-derived CBD markets.”


Luxembourg to be first European country to legalise cannabis💯

Luxembourg has called on its EU neighbours to relax their drug laws as its health minister confirmed plans to become the first European country to legalise cannabis production and consumption.

Luxembourg will follow Canada in legalising the possession of 30 grams of cannabis.

“This drug policy we had over the last 50 years did not work,” Etienne Schneider told Politico. “Forbidding everything made it just more interesting to young people … I’m hoping all of us will get a more open-minded attitude toward drugs.”

Tax revenues will be reinvested in drug education and addiction treatment programmes

Draft legislation is expected to be unveiled later this year providing further detail on the types of cannabis that will be on sale and the level of tax that will be imposed.

Residents over the age of 18 are expected to be able to buy the drug for recreational use legally within two years. The state will regulate production and distribution through a cannabis agency.

Schneider said the legislation was likely to include a ban on non-residents buying cannabis in order to dissuade drug-tourism. Home-growing is also likely to be prohibited.

Aurora Cannabis Update Fourth Quarter

Aurora the Canadian company defining the future of cannabis worldwide, today provided a corporate update on selected financial metrics for the fourth quarter of the Company’s Fiscal 2019 (“Q4 2019”) period ended June 30, 2019.

Based on a preliminary (unaudited) review, the Company anticipates net revenues for the quarter ended June 30, 2019of between $100 million and $107 million (net of excise taxes), compared to $19.1 million in the period ended June 30, 2018, and compared to $65.1 million for the previous quarter ended March 31, 2019.  


Fiscal Q4 2019 net cannabis revenue is expected to be between $90 million and $95 million, with growth anticipated across all key business segments including medical, both Canadian and international, and consumer markets.  The Company anticipates total net revenues for the fiscal year ended June 30, 2019 to be between $249 million – $256 million.


The Company expects to report that production available for sale for Q4 2019 will be at the upper end of the range between 25,000 kg and 30,000 kg, ahead of previous guidance of 25,000 kgs.

Aurora’s management team and Board of Directors continue to drive a culture rooted in quality, transparency, and regulatory compliance. Aurora has grown both organically and through acquisitions of companies with shared visions, and today this culture is ingrained in Aurora’s over 2,500 employees across the globe.

“Our Q4 2019 guidance highlights Aurora’s continued leadership,” said Terry Booth, CEO of Aurora. “We set out to be best-in-class cultivators, and through carefully evaluated acquisitions, that vision continues to drive exceptional results today. We are the leader in cultivation capacity, production available for sale and revenues for cannabis in the Canadian medical and consumer markets.

We continue to lead the build out of European and other international medical cannabis markets. Our success to date comes from a focus on quality, regulatory compliance, appropriate Board of Directors oversight, and delivering a profitable, low risk and sustainable business for our shareholders.”


Choom Acquires 7 Additional Cannabis Retail Locations in BC and Alberta

Choom™ (CSE: CHOO; OTCQB: CHOOF), an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce that it has signed a definitive agreement to acquire The Green Room, a popular cannabis retail store chain which has operated since 2016.

The agreement involves the purchase of location assets from The Green Room which includes three (3) locations in British Columbia and four (4) locations in Alberta. The Green Room locations in Alberta and British Columbia feature several premiere locations for cannabis retail stores with multiple years of successful operation.

“Green Room was a highly successful operator that originally opened in Vancouver as a compassion club offering medicinal cannabis to their patients.  Choom looks to build on the good reputation they have in the communities they served and open legal cannabis retail stores in their successful locations.” states Chris Bogart, President and CEO of Choom “Our priority for these locations are to bring our unique Choom experience that encourages sharing education with consumers about the safe and responsible use of cannabis.”

The two locations in Vancouver are expecting to receive development permits to operate legal cannabis retail stores. The location in Squamish has municipal approval and is awaiting approval from the Liquor & Cannabis Regulation Branch of British Columbia (“LCRB”). 


 Three of the four acquired locations in Alberta have received development permits from the applicable municipalities to operate cannabis retail stores.  Choom will submit its applications for cannabis retail store licenses to the Alberta Gaming, Liquor & Cannabis Commission (“AGLC”) at its earliest convenience.

Building Europe’s Medical Cannabis Industry💯

The leaders of the medical cannabis industry in the heart of the city of London

On the 24th-25th of June 2019

the Southbank CentrE

#CannabisEuropa @southbankcentre

This two-day event will explore the latest developments in the UK market and the professionalisation of the industry across the European continent


Aurora Cannabis Inc (TSE:ACB) on UK becoming Medical Cannabis Global Leader

Aurora Cannabis Inc (TSX:ACB)(NYSE:ACB)(FRA:21P) CCO Cam Battley visits James at the Cannabis Europa Conference in London, UK. Cam Battley was a guest speaker and discusses the potential for the UK to be a leader in medical cannabis on a global basis. While regulations at the moment make it a challenging process to provide medical patients with accessible cannabis products, Battley knows that Aurora can overcome those hurdles.

Andrew Neil chairing latest session #CannabisEuropa

BBC’s Andrew Neil hosts a panel with Conservative MP Crispin Blunt, Lib Dem Norman Lamb and PCC for Avon and Somerset Sue Mountstevens… Lamb holding Mountstevens to task

Good to see norman lamb and Crispin Blunt making a strong case for legalising and regulating recreational cannabis for adults.

“There is a price to be paid for being cautious” says normanlamb as to whether the UK can wait years to see the evidence from Canada #cannabiseuropa #CannabisEuropa

Lots of great podcasts being recorded here today at CannabisEuropa, including the VoltefaceHub Podcast, TheCannabisCon2 and ValensGroWorks

Prime Minister of Malta Joseph Muscat speaks at CannabisEuropa about how legalising & regulating research & medicinalcannabis production has brought investment & jobs to the country.

Lesotho was first African country to legalise cultivation and export of medicinalcannabis. Prime Minister of the Kingdom of Lesotho, Monyane Moleleki, speaks at CannabisEuropa about how medicinal cannabis has been key to Lesotho’s growth & poverty eradication strategy.


deepak anand discussing CBD legalization, and new regulations rolling out on MidasLetter

“The Responsible Face of the Industry” panel at cannabiseuropa

MP Connie cowan now discussing the ‘ignorance’ of the Home Office for failing to open dialogues regarding the access of cannabis for patients.

Crispin Blunt currently in the Valens PodBooth at Cannabis Europa talking about Britain’s political strides towards more progressive cannabis policy.

“Social justice is core to this community, and it’s a community not just an industry”

Jonathan Zaid of Aurora

With over 80 speakers across 18 talks, Cannabis Europa London has something for everybody.

Our panelists will be discussing the most pressing issues facing the European industry today, analysing the developments of the last 12 months and looking at how medical cannabis has permeated the mainstream.

With a line up of prominent politicians and policymakers, inspirational business leaders and healthcare professionals, unwavering advocates and ingenious entrepreneurs, we are shaping the debate across the continent.

Aurora Cannabis Extends Exclusive Supply Relationship with Luxembourg

Aurora Deutschland has been selected by the Luxembourg Health Ministry as the exclusive supplier in a public bid to supply the second delivery of medical cannabis to Luxembourg.


Under the terms of the bid, the medical cannabis produced will be sold to Luxembourg’s Division de la Pharmacie et des Medicaments, representing the second time the Company has received an order directly from the Luxembourg government. While the initial bid quantities are small, the award confirms Aurora’s position as a trusted and preferred supplier to international jurisdictions and reflects the Company’s ability to work with local governments and regulators in complex, restricted markets.

“We are proud to continue serving as the exclusive supplier of medical cannabis to the Luxembourg Health Ministry,” said Neil Belot, Chief Global Business Development Officer. “Adding to the many achievements of our European team, which also includes our recent selection as one of only three companies to establish domestic production in Germany, our expanded supply agreement with Luxembourg reinforces Aurora’s ability to act as a trusted partner that can readily meet the complex needs of diverse international markets.”

Maximilian Weinberg, Associate Director of Aurora’s EU Business Development, added, “As the established market leader across Europe, Aurora is exceptionally well positioned to leverage our significant early mover advantage to accommodate the growth of new medical cannabis markets as opportunities arise. We’re proud of our teams’ achievements to date and look forward to supplying patients in Luxembourg with improved access to high quality medical cannabis.”

About AuroraMJ

Headquartered in Edmonton, Alberta, Canada with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora is one of the world’s largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale production of high-quality product at low cost. Intended to be replicable and scalable globally, our production facilities are designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs. Each of Aurora’s facilities is built to meet EU GMP standards. EU GMP certification has been granted to Aurora’s first production facility in Mountain View County, the MedReleaf Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland.

In addition to the Company’s rapid organic growth and strong execution on strategic M&A, which to date includes 16 wholly owned subsidiary companies – MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs, and Whistler – Aurora is distinguished by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic partnerships with a range of leading innovators, including:

Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV: HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private), Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI), and EnWave Corporation (TSXV: ENW).

Aurora’s Common Shares trade on the TSX and NYSE under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index.


Aphria Completes German Tender Process and Receives Fifth Culitvation License in Germany

Aphria Inc, today announced that its German subsidiary Aphria Deutschland GmbH (“Aphria Germany“) had been awarded a fifth lot for the cultivation of medical cannabis in Germany as part of the Company’s previously awarded license from the German Federal Institute for Drugs and Medical Devices (“BfArM“).

The additional lot was provisionally awarded to Aphria Germany in April and was secured following a review by a German court, which affirmed the original decision by the BfArM.

With this decision, Aphria Germany won the maximum output from the German tender process – a total of five lots – and stands as the only licensed producer in Germany with the permission to grow all three strains of medical cannabis approved by the BfArM.

“We are thrilled about our successful conclusion to the German tender process, which has awarded Aphria with the most comprehensive license in the country,” said Hendrik Knopp, Managing Director of Aphria Germany.

Aphria Germany is building its over 8,000 square meter indoor growing facility in Neumünster and is completing work on a state-of-the-art GMP-certified cannabis vault in Bad Bramstedt for the import of cannabis flowers and oil from Canada, Australia and Denmark. Aphria Germany also holds a 25.1% interest in Berlin-based Schöneberg Hospital, which provides access to both doctors and patients for education on the benefits of medical cannabinoids.

The company also recently introduced CannRelief, a CBD-based nutraceutical and cosmetics product line for the German market, produced in the EU and distributed by CC Pharma, a subsidiary of Aphria with access to more than 13,000 pharmacies throughout Germany.

Canopy Growth Acquires Germany’s C3 Cannabinoid Compound Company

The all cash-acquisition for €225.9 million

“What this boils down to is greater choice,” said Bruce Linton, Chairman & Co-CEO, Canopy Growth. “This acquisition will allow us to offer more options to physicians across Europe, accelerate our commercial sales and increase our economic footprint on the continent, and drive forward new innovations. Our goal is to build on C3‘s extraordinary reputation and decades of success as we move to an innovative continuum of medical cannabis therapies that will enable physicians globally to better treat their patients.”

Three companies were chosen to cultivate medical marijuana in Germany.

This is a watershed moment for  operations in Germany


We are very proud to have been selected as one of only three companies by the German government, which is a great achievement by our team. Having the highest rated concept is a strong validation of the Aurora Standard cultivation philosophy, as well as of our track record in the delivery of safe and high-quality medical cannabis products to the German system


Aphria Awarded Provisional Approval in Germany for Cannabis Cultivation License


Aphria is proud to have been selected as a successful applicant in the German tender process, a testament to our high production quality standards,” said Hendrik Knopp, Managing Director of Aphria Germany. “The decision from BfArM is a validation of our strategic approach to supporting the German medical cannabis market, including with high-quality, domestic production to secure vital supply for patients. We are very pleased with our continued business momentum in Germany.”

Wayland Selected as One of Three Groups for Cannabis Production Licenses in Germany


From the beginning, the market opportunity for medical cannabis in Germany has been a key part of Wayland’s global growth strategy. The Company has always prioritized Germany as one of the most exciting medical cannabis markets in the world given its progressive regulations, rapidly expanding the patient population, and insurance coverage for over sixty percent (60%) of prescriptions.

European Cannabis Industry Update Report

While the American cannabis industry deals with both unparalleled opportunity and new risks, Europe is setting itself up for a spring that is going to be verdant.

The ongoing drumbeat for reform in countries across the continent is bringing both money and high-grade medical product into the market. Even if volume is still really at a trickle, it will rapidly widen to a steady stream. It is also very clear that the next two to three quarters are going to deliver news that the cannabiz has arrived, and with authority.

The following is an overview of what is happening, where, and with an eye to informing foreign investors, in particular, about new opportunities in an awakening market.


Without a doubt, the country is priming itself for a medical market that is going to be large and partially government supported, driving regulation of medical use across the continent. On top of that, the idea of selling 28 grams (1 oz) of product to end consumers who only pay about $12 for their medication has gotten the attention of global producers. Opportunities here for those who did not submit a bid for federal cultivation (see the big Canadian LPs) are still unfolding.

german flag

However here is what is now on the table: an import market that cannot get enough cheap, GMP certified product. Producers from Australia to Uruguay are now actively hunting for a way in, even if cutting a supply deal for the next 18 – 24 months as the German green machine starts to kick into production-ready status. What a bad time for Israel to be so publicly out of the ex-im biz! In fact, Israeli entrepreneurs are scouring the country for opportunities into the market another way (and there are a few efforts afoot in a sleeping giant of a market waking up from a long snooze to find they cannot get enough product). Right now, however, the legal market is absolutely dominated by Canopy, Aurora, Aphria and Tilray along with Dutch Bedrocan.

The German parliament is clearly also going to do something about another piece of reform which will also drive market expansion – starting with announcement of additional cultivation possibilities (potentially this time even open to German firms). On Friday, the day after the British parliament wrangled over the same thing, the German Bundestag debated decriminalization along with a few other hot button topics (like abortion). With only the AfD (right wing) still in the “lock ‘em up camp,” and even the head of the police calling for reform, it is clear that decriminalization is on the legislative agenda this year.

Spain, Italy, Switzerland, Portugal, Denmark & Holland

While it may seem presumptuous to lump all these very different countries under one label, the reality is that the level of reform is generally in a similar state (transition to medical), and that drives potential political and market risk as well as evaluation of investment decisions.

aurora logoIn Spain, federal reform has not come yet, but medical deals involving pharmaceutical companies (both exclusively cannabinoid focussed and otherwise) are afoot. Plus of course there is Barcelona (the Colorado of the country in many ways).

Italy, Portugal and Denmark are all the battlegrounds for the big Canadian (and German) companies now set on having a country-by-country footprint in opening markets across the EU (see Canopy, Aurora, Aphria and their German counterparts of Spektrum Cannabis, Pedianos and Nuuvera). Licensing is political, happening at a high level, and only for those with the bank to back deals that come with high capex attached. That said, there are lucrative opportunities for those with local contacts and liquidity.Nuuvera logo

Holland is another animal altogether, but for the most part everyone is so confused about the state of reform domestically that the only people really in position to take advantage of it are the Dutch, at least for now. That said, Dutch-based plays (in part financed by Canadian backing) for other Euro markets are absolutely underway. Who else has so much experience here, let’s be honest? Regardless, investments in these canna markets, particularly for the Euro-focussed but North American investor, for now, will tend to be through public stock acquisitions of Canadian parents or direct investments in Dutch companies (see Bedrocan, but they are not the only game in town).

Switzerland, for the most part, is setting its own pace, but reform here means the CBD market, including for medical grade imports, is a place for the savvy medical investor to look for cultivation and ex-im opportunities. Including in the home-grown, Swiss pharma space.


The recent pronouncement of government officials that Greece was opening its doors to investment and a medical cannabis business means that there will be a federally legal, EU country that is promoting both investment and tourism opportunities just for domestic consumption, let alone export. Scouts from all the major canna companies are combing both the Greek mainland and its islands.


If there was ever such a thing as a “virgin” cannabis market, Poland might well qualify. For those distributors with cheap product that has not (yet) found a home, the country is poised to start to announce (at least) distribution deals to pharmacies with producers now establishing themselves in other markets. Medical legislation has just changed, in other words, but nothing else is in place. And with Polish patients now having, literally, to scour the continent for a product not to mention foot the bill for the travel costs to get it, the next obvious step is a national pharmacy chain distribution deal or two with producers from all over the world now looking for Euro market entry possibilities. Domestic production is some time off.

reform in countries across the continent is bringing both money and high-grade medical product into the market

If there were such a thing as the “Berlin” of the cannabis market in Europe (namely sexy but poor), it is probably going to be here. Cheap production markets and opening opportunities for export across the EU for high quality, low cost cannabis are not going unnoticed. Look for interesting plays and opportunities across the region. Scouts from the big international canna companies already are.

The UK

Britain comes last because of the political uncertainty in general, surrounding the island. However, last week Parliament appeared on the verge of being embarrassed into acting on at least medical reform. There will be a market here and of course, there is already one globally known cannabis company with a 19-year track record and a monopoly license on canna-medical research and production (GW Pharmaceuticals) that calls the British Isles home. This will be a no-brainer, particularly for foreign English-speaking investors still leery of continental Europe. However it will also be highly politically connected. Expect to see a few quick arranged marriages between such landed gentry and foreign capital – potentially even this year.

cbd #cbduk #cannabis #medicalcannabis #hemp

CBD WeedMD 💚


WHSmith will launch with the Ignite ONE device, a rechargeable vape pen compatible with Ignite CBD pods and Ignite branded tinctures. 




Both WHSmith and Ignite will coordinate future product introductions, including additional vape and health and beauty applications, in concert with Ignite’s product roadmap.

Retail sites featuring the Ignite products include Heathrow Terminals 2 through 5, Gatwick North and South, Birmingham Airport, Liverpool Airport, London City Airport, Manchester Airport (Terminal 1), and Kings Cross Station.  These sites offer exposure to a total of approximately 192 million travel passengers per year.

With over 600 stores on the high street and another 800+ travel stores at airports, train stations, hospitals, workplaces and motorway services, WHSmith is one of the UK’s leading retail groups and a household name.  The first newsagent in the Smith family name opened in 1792, and the company, WHSmith, was created in 1828.




WeedMD continues to make solid progress and we’re proud to post another record quarter that highlights the strength of our operations and the demand for our products

Our gross margins improved to 46% as we realized scale in our cultivation operations and continued optimizing our supply chain.

With another 10 newly-licensed 10,000 sq. ft. cultivation rooms coming online alongside our 27-acre outdoor harvest, we expect to realize some of the best cultivation margins in the industry.”

WeedMD outdoor cannabis cultivation update – August 2019

Check out the latest progress update of our outdoor grow & production.

next stage of production leading up to a fall harvest, including our plants & people strategy for success.

plants – they’re flowering!


Built on TruTrace’s proprietary StrainSecure™ system which focuses on cannabis product testing and verification to confirm origin, authenticity and quality.

WeedMD is the first and only licensed producer to have 40 strains registered in the program. This technology helps in the protection of WeedMD’s unique strains and assists its customers, including Shoppers Drug Mart, with strain and product authenticity.

StrainSecure’s blockchain-enabled technology allows TruTrace to collect plant testing data and perform genomic verification on the plants to be stored and tracked in a database.

It serves as the central hub for identity management, asset tracking, validation and product authentication, as well as a master registry for standardized testing, product verification, and quality assurance.

WeedMD Secures Health Canada Approval for 20 Additional Cannabis Cultivation and Processing Rooms

WeedMD a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce it has secured a Health Canada licence amendment approval to expand production into ten additional 10,000 square foot cultivation rooms and ten new processing rooms at its state-of-the-art hybrid greenhouse in Strathroy, Ontario.

Licensing of the 20 additional rooms and ancillary space more than doubles WeedMD’s licensed greenhouse production space in Strathroy. Additionally, 27-acres of outdoor grow on the property was licensed and planted in June of this year.

With a total of eighteen 10,000 square foot hybrid cultivation rooms now licensed, WeedMD’s annual greenhouse cannabis production capacity is more than 20,000 kgs, with more than 25,000 kgs of incremental biomass forecasted to be harvested from the outdoor cultivation in Q4, 2019. The 10 new processing rooms will be used for drying, trimming and processing cannabis.


Widely recognized for its engaging marketing content, the Ignite brand is established internationally and recognized for its premium suite of cannabis and CBD products. The initial product launch will include a variety of THC and CBD products for the Canadian market.

“We truly believe quality flower is at the heart of every Ignite product we market. It’s at the core of everything we make and represents an unwavering dedication to deliver premium cannabis and CBD products worldwide and now especially here in Canada,” said Jim McCormick, President of Ignite. “Ignite represents cannabis and CBD at its finest and CX Industries and WeedMD are the perfect Canadian partners who share the same drive for quality.”

WeedMD Launches Cannabis Extraction Affiliate CX Industries

The launch of CX Industries represents the next step in the evolution of WeedMD. The marriage of consistent low-cost input material from our cultivation platform with our fully-licensed extraction hub in Aylmer truly sets us apart.

 Our management team is now working with strategic partners to provide a platform for entrepreneurs and seasoned brands to enter the concentrates market, building on our history of collaborating successfully with our peers in the cannabis industry,” said Keith Merker, CEO of WeedMD.

“We have a solid reputation for executing on our production platforms – rooted in our integrity and transparency, combined with our ability to scale.  CX offers world-class extraction and end-to-end production solutions as the market readies for the launch of extracts later this year.”


WeedMD is pleased to announce it has completed the outdoor planting of more than 20,000 fully-rooted cannabis plants at its Strathroy, Ontario property.

Clones were rooted in organic material for over four weeks to reach acclimatization and optimal transplant size 

WeedMD is one of the first licensed producers in Canada to commence outdoor grow operations with its first harvest expected in October 2019. 


“With our outdoor grow now fully operational, WeedMD has one of the most compelling and low-cost cultivation platforms in Canada,” said Keith Merker, CEO, WeedMD. “

Planting a variety of proprietary cannabis strains outdoors in June positions the Company to meet and exceed our production forecasts. WeedMD recently launched its adult-use brand Color Cannabis™, and with the introduction of new cannabis extract products in late 2019, we expect to have one of the largest, low-cost supplies of biomass to position ourselves vertically for the emerging extract market.”

Phase I includes the first 27 of 100 available acres at its Strathroy property

Construction of fencing, security, irrigation and other required infrastructure completed on time and within a fully-funded $2 million budget

73 additional acres of production planned for Phase II in 2020 on the existing property

Municipal approval secured

Operational synergies with outdoor cultivation directly adjacent to WeedMD’s existing propagation operations within its licenced greenhouse facility

All infrastructure and staffing resources exist onsite with a proven team dedicated and experienced in outdoor grow

WeedMD’s cultivation team brings significant experience growing cannabis outdoors locally

Selected strains proven to excel outdoors in southwestern Ontario

Growing from rooted plants allows for higher yields, survival rates and consistency when compared to starting from seed

Optimized plan with strains grouped with similar cultivation profiles in five planting zones

Nothing to see here but 27-acres of outdoor grow!

“Some plants are already close to 4ft tall.”

It’s been 1mo since we planted cannabis outdoors & all is progressing to schedule.

“Everything is growing amazingly well w, some strains likely to start flowering in 3-4 wks,”

cannabis plants are getting so tall and heavy that we’ve had to bring in some extra support.

Weekly update from our outdoor cannabis grow. Many plants are starting to reach over 6 feet tall. Way to go team! CannabisCanada

Do “trellis” more… our cannabis plants are getting so tall & heavy that we’ve started installing trellis netting. It’s a good sign that we’ve started into the next stage of vegetation – all on schedule for these beauties. CannabisCanada


Mile High Labs CBD UK💯

Cbd Labs Belfast Northern Ireland 💚

Mile High Labs, the largest extractor of CBD isolate in the world

Northern Ireland sales into the UK and Europe, cementing its position as a supplier of CBD globally.

European expansion efforts for the Company. This location is strategically important to Mile High Labs, as it enables the Company to fulfill regional orders of all sizes quickly, allows for the servicing and support of customers locally and serves as a borderless gateway to the rest of the European CBD market.

“We are very excited to officially launch European operations with our first sales into the UK and EU,” said John Wallace, Managing Director of Mile High Labs UK/EU.

“Quality and consistency are of paramount importance in the European market, and we are proud to bring Mile High Labs’ products and standards to customers locally.

Having an on-the-ground presence helps us provide the best service and support to current customers in the region as well as new ones that understand the tremendous opportunity in this burgeoning market.”

“Our expansion is a testament to the global consumer demand for CBD,” said Jason Roth, CEO of Mile High Labs. “Wherever our customers are around the world, we want to support them, and we are committed to bringing the highest quality standards to the European CBD market and beyond.”

Mile High Labs’ new Belfast center will provide the Company with three significant advantages moving forward

(1) it opens up a low-cost distribution center to serve the UK and European markets

(2) it lowers the Company’s effective corporate tax rate via the UK patent box system

(3) it creates new business opportunities through the Company’s close relationship with Invest Northern Ireland.


Colorado company Mile High Labs has established its first European base in Northern Ireland and recently recorded its first sales in UK and Europe.

Mile High, which describes itself as the ‘largest extractor of CBD isolate in the world’, began operations in Belfast, last year, and in a press release says it has since built out a dedicated team to lead its expansion in Europe.

John Wallace, Managing Director of Mile High Labs U.K./E.U. said: “We are very excited to officially launch European operations with our first sales into the U.K. and E.U. Quality and consistency are of paramount importance in the European market, and we are proud to bring Mile High Labs’ products and standards to customers locally.”

“Having an on-the-ground presence helps us provide the best service and support to current customers in the region as well as new ones that understand the tremendous opportunity in this burgeoning market.”

A Mother’s Campaign Prompts UK Law Change

Jason Roth, CEO of Mile High Labs, added: “Our expansion is a testament to the global consumer demand for CBD. Wherever our customers are around the world, we want to support them, and we are committed to bringing the highest quality standards to the European CBD market and beyond.”

Mile High Labs says the Belfast operation opens up a low-cost distribution center to serve the UK and European markets, will lower its corporate tax rate via the UK patent box system, and will create new business opportunities through the company’s close relationship with Invest Northern Ireland.

Cannabis medication has become increasingly high profile in Northern Ireland. Tyrone county woman Charlotte Caldwell helped change UK legislation last year after securing a licence from the Home Secretary Sajid Javid to import cannabis medicine to treat her son Billy’s epilepsy.

In October, last year, Mile High Labs secured  $35 million from institutional and private equity investors to expand the production capacity of its CBD extracts and fund its international expansion. In a press statement at the time Mr Hilley said: “We believe the CBD market is in the early stages of a 20-year secular growth trend, the size and scope of which the world’s largest consumer of packaged goods cannot ignore.

“We are already the CBD platform of choice for many of the market’s most recognizable brands and we welcome the chance to work with anyone seeking to explore this immense opportunity.”

Mile High Monster

Last month the company unveiled its ‘Mile High Monster’ – a mobile CBD extractor – which is installed directly on a hemp farm to work like an oil derrick.

It’s the first commercial scale, patent-pending extractor of its type with the company saying it can process about 50 acres of hemp per day into six barrels of CBD oil. The new extractor, the result of years of research and development, will help meet demand for the oil, it says.

The company’s first Mile High Monster was set up in eastern Colorado in March and the second will begin operating in southern Colorado this month.

Choom is pleased to announce that Choom Niagara, the first legal, adult use cannabis store to operate in Niagara Falls, ON has produced over $49,000 in sales on its opening day.💚


“We are really happy with the turnout we had for Choom Niagara’s opening day.” states Chris Bogart, President and CEO of Choom

“We’ve had a lot of support from the local community, and we’re excited to bring Choom to Niagara Falls.

The feedback from our customers has been fantastic, and that is a testament to our dedicated staff and in-store experience. 

Doing  $49,000 in sales on the first day of operation is a great milestone for us and our team who have worked so hard to get where we are today